-
Kexing Pharmaceutical Partners with Yabao to Distribute Generic Nexavar in Ten Countries
•
China-based Kexing Pharmaceutical (SHA: 688136) has entered into an overseas cooperation agreement with fellow domestic firm Yabao Pharmaceutical Group Co., Ltd. (SHA: 600351) to distribute a generic version of Bayer (ETR: BAYN)’s Nexavar (sorafenib). Under this agreement, Kexing will serve as the exclusive agent for the tyrosine kinase inhibitor (TKI)…
-
Fujian Province Issues Provisional Regulations for Managing Medical Representative Visits
•
The Fujian provincial health commission and medical products administration have jointly issued the “Provisional Regulations on the Management of Reception of Medical Representatives by Staff of Public Medical Institutions in Fujian Province.” These regulations mandate that pharmaceutical representatives engaging in academic promotion activities related to their products within medical institutions…
-
GenScript’s Subsidiary Legend Biotech Gets CHMP Nod for Carvykti Label Expansion in Multiple Myeloma
•
GenScript Biotech Corporation (HKG: 1548), a China-based Contract Research Organization (CRO), has announced that its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the label expansion of its (BCMA)-directed chimeric antigen receptor T…
-
Celltrion’s Infliximab Biosimilar Shows Promising Long-Term Efficacy and Safety in CD and UC
•
South Korean biopharmaceutical company Celltrion (KRX: 068270) has presented positive long-term efficacy and safety data for its infliximab biosimilar in the treatment of Crohn’s disease (CD) and ulcerative colitis (UC). The biosimilar offers the advantage of subcutaneous administration, providing a more convenient alternative to Johnson & Johnson’s (J&J; NYSE: JNJ)…
-
Takeda’s Recombinant Pig FVIII Drug for Acquired Hemophilia A Approved in China
•
The National Medical Products Administration (NMPA) website has indicated that Takeda (TYO: 4502)’s Obizur (susoctocog alfa), intended for on-demand treatment and control of bleeding events in adult patients with acquired hemophilia A, has received approval in China. This drug marks the first recombinant pig FVIII (rpFVIII) to be approved by…
-
Mabwell Bioscience Cancels Licensing Agreements with Yangtze River Pharma for Two Drug Candidates
•
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced the cancellation of licensing agreements with Yangtze River Pharmaceutical Group for two of its drug candidates: 8MW0511, a recombinant (yeast secreted) human serum albumin human granulocyte colony-stimulating factor (I) fusion protein for injection, and 9MW1111,…
-
Mabwell Bioscience’s Nectin-4 Targeting ADC Earns FDA Fast-Track Designation for Esophageal Cancer
•
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced that it has received fast-track designation from the US Food and Drug Administration (FDA) for its antibody drug conjugate (ADC) 9MW2821. This candidate targets Nectin-4 and is under investigation for the treatment of advanced, recurrent,…
-
Boehringer-Ingelheim Partners with CBmed to Accelerate First-in-Class Cancer Medicines Development
•
Boehringer-Ingelheim, a German pharmaceutical giant, has entered into a long-term strategic partnership with Austria-based CBmed GmbH Center for Biomarker Research in Medicine (CBmed). The collaboration aims to leverage translational medicine approaches to expedite the development of first-in-class oncology drugs, with the ultimate goal of transforming the lives of cancer patients…
